References
Kälviäinen R, Eriksson K, Parviainen I. Refractory generalised convulsive status epilepticus: a guide to treatment. CNS Drugs 2005; 19(9): 759–68
Logroscino G, Hesdorffer DC, Cascino GD, et al. Long-term mortality after a first episode of status epilepticus. Neurology 2002; 58: 537–41
Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59(2): 205–10
Claassen J, Hirsch LJ, Emerson RG, et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systemic review. Epilepsia 2002; 43: 144–53
Metsäranta P, Koivikko M, Peltola J, et al. Outcome after prolonged convulsive seizures in 186 children: low morbidity, no mortality. Dev Med Child Neurol 2004; 46(1): 4–8
Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339: 792–98
Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993; 43: 483–88
British national formulary. No. 51. London: The Pharmaceutical Press, 2006 Mar
Kriel RL, Cloyd JC, Pellock JM, et al. Rectal diazepam gel for treatment of acute repetitive seizures. Pediatr Neurol 1999; 20: 282–8
McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005; 366: 205–10
Hirsch LJ, Claassen J. The current state of treatment of status epilepticus. Curr Neurol Neurosci Rep 2002; 2: 345–56
Boucher BA, Feler CA, Dean JC, et al. The safety, tolerability and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Pharmacotherapy 1996; 16(4): 638–45
Lowenstein DH. Treatment options for status epilepticus. Curr Opin Pharmacol 2003; 3: 6–11
Hodges BM, Mazure JE. Intravenous valproate in status epilepticus. Ann Pharmacother 2001; 35: 1465–70
White JR, Santos CS. Intravenous valproate associated with significant hypotension in the treatment of status epilepticus. J Child Neurol 1999; 14: 822–3
Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: a survey of neurologists. J Neurol Sci 2002; 211(1-2): 37–40
Shorvon SD. The management of status epilepticus. J Neurol Neurosurg Psychiatry 2001; 70Suppl. 11: ii22–7
McBurney JW, Teiken PJ, Moon MR. Propofol for treating status epilepticus. J Epilepsy 1994; 7: 21–2
Wälder B, Tramer MR, Seeck M. Seizure-like phenomena and propofol. Neurology 2002; 58: 1327–32
DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent non-convulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998; 39: 833–40
Granata T, Fusco L, Gobbi G, et al. Experience with immunomodulatory treatments in Rasmussen’s encephalitis. Neurology 2003; 61: 1807–10
Ma X, Liporace J, O’Connor MJ, et al. Neurosurgical treatment of medically intractable status epilepticus. Epilepsy Res 2001; 46(1): 33–8
Rights and permissions
About this article
Cite this article
Aggressive and early treatment of refractory generalised convulsive status epilepticus improves response and outcome. Drugs Ther. Perspect 22, 12–16 (2006). https://doi.org/10.2165/00042310-200622070-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200622070-00004